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Objective—To examine the effect of telmisartan or hydrochlorothiazide (HCT) 
on the control of urinary albumin excretion (UAE) in patients with isolated 
systolic hypertension (ISH) and unselected for albuminuria in a pre-planned 
substudy of a large, multicentre, double-blind, placebo-controlled, randomized 
study. Methods—The Angiotensin II Receptor Antagonist Micardis in Isolated 
Systolic hypertension (ARAMIS) study compared the antihypertensive efficacy 
after 6 weeks of once-daily fixed doses of telmisartan 20, 40 or 80 mg versus 
HCT 12.5 mg or placebo in patients  (n = 1039, age 35-84 years) with ISH 
(seated blood pressure (BP) 150-179/< 90 mmHg). The prospective substudy 
analysed UAE using spot morning samples. Results—Urinary albumin (> 2.2-
901.6 mg/L) was detected at baseline in 614/918 patients, who were included in 
the substudy analysis. In the telmisartan group (n = 354, all doses combined), a 
median reduction in UAE from baseline of 14.1% (95% confidence intervals 7.3, 
21.8) was observed versus 1.1% (-13.5, 16.0) and 2.7% (-0.9, 19.9) in the HCT (n 
= 140) and placebo (n = 120) groups, respectively. The difference between 
telmisartan and HCT was significant (p = 0.017). Reductions in UAE with 
telmisartan were observed in patients with baseline normoalbuminuria, 
microalbuminuria or macroalbuminuria. Telmisartan and HCT produced 
comparable reductions in systolic BP in these patients. Conclusion—In patients 
with ISH and unselected for baseline albuminuria, telmisartan 20-80 mg after 6 
weeks’ treatment afforded significantly greater lowering of UAE than HCT 12.5 
mg, irrespective of the baseline UAE, and despite comparable reductions in 
systolic BP with both drugs.   
 
 
   solated systolic hypertension (ISH) is an important treatment target, recognized as a 
dominant risk factor for heart disease, stroke and renal failure (1,2). Microalbuminuria 
and macroalbuminuria are also widely accepted risk factors for cardiovascular and renal 
disease in patients with diabetes (3,4) and hypertension (5-7). In patients with urinary 
albumin excretion (UAE) below the definition of microalbuminuria (< 20 mg/L), 
increased cardiovascular and renal risk still exists (8), and epidemiological studies show 
that such individuals are at increased risk of cardiovascular death (9) and all-cause 
mortality (9,10). Moreover, in hypertensive patients with left ventricular hypertrophy, 
elevated UAE results in heightened cardiovascular risk without any thresholds for 
albuminuria (11). In patients with ISH, macroalbuminuria is predictive of cardiovascular 
mortality and cardiovascular and renal morbidity (12), but the relationship between 
slightly elevated UAE in these patients and cardiovascular risk has not been studied. 
I
Antihypertensive treatment should ideally not only lower the risk associated with 
high blood pressure, but also lower UAE and thus reduce its associated risk (13). Agents 
targeting the renin-angiotensin-aldosterone system (RAAS) lower blood pressure and are 
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particularly effective in reducing microalbuminuria and macroalbuminuria (14). This 
reduction of UAE contributes independently to improved cardiovascular and renal 
outcomes in many different patient groups (15-21). 
Until now there has been no information on the effects of different 
antihypertensive agents on UAE in hypertensive patients with UAE below 
microalbuminuric levels. Data in the present report are derived from a pre-planned 
substudy of a large-scale, multicentre study—Angiotensin II Receptor Antagonist 
telmisartan (Micardis) in Isolated Systolic hypertension (ARAMIS) (22). The purpose of 
the main study was to identify telmisartan doses that are more effective than placebo and 
non-inferior to hydrochlorothiazide (HCT) in lowering systolic blood pressure (SBP) in 
patients with ISH and that are well tolerated. The primary objective of this substudy was 
to evaluate the effect of different once-daily telmisartan doses (20, 40 and 80 mg) on 
UAE in patients with ISH and with UAE of any degree (including below the threshold 
for microalbuminuria), compared with once-daily HCT 12.5 mg or placebo. To 
determine whether any effect on UAE is independent of blood pressure control, 
efficacies of the different telmisartan doses on the reduction in SBP and diastolic blood 
pressure (DBP) were compared with those of HCT and placebo.  
 
PATIENTS AND METHODS 
Study population 
A  total   of   1039  patients  with  ISH   (seated  SBP/DBP  150-179/<  90 mmHg)  were 
randomized to treatment in the ARAMIS study, which was conducted in 17 countries in 
Europe, Australia and South Africa (22). Participants of either sex and between 35 and 
84 years of age were recruited from primary-care or specialist hypertension centres. 
Patients receiving antihypertensive medication immediately prior to the study could only 
be enrolled if it was considered that withdrawal of that treatment and the possible 
receipt of up to 10 weeks’ placebo would not compromise their health. Exclusion 
criteria comprised secondary hypertension, hepatic and/or renal dysfunction (defined as 
serum creatinine > 159 µmol/L (> 1.8 mg/dL)), clinically relevant hypo- or 
hyperkalaemia, uncorrected volume or sodium depletion, primary aldosteronism, 
symptomatic cardio- or cerebrovascular disease, previous percutaneous transluminal 
angioplasty or coronary artery bypass grafting, inadequately controlled or recently 
stabilized type 2 diabetes mellitus, type 1 diabetes mellitus, hypersensitivity to 
telmisartan or HCT, or gout. Women who were pregnant, nursing or of childbearing 
potential were not eligible. Patients from Australia (n = 65) were excluded from the 
substudy because correct collection of urine was not possible for UAE assessment. All 
patients gave written, informed consent.  
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Study design 
Local institutional review boards approved the protocol for the randomized, double-
blind, placebo-controlled, parallel-group substudy. After screening, eligible patients 
entered a single-blind run-in period before randomization. If a patient was not receiving 
antihypertensive treatment at the time of enrolment, placebo was administered for 2 
weeks. For patients who had received antihypertensive treatment immediately prior to 
enrolment, the placebo washout period was extended to 4 weeks. Thereafter, patients 
were randomized to 6 weeks’ double-blind, once-daily treatment with telmisartan 20, 40 
or 80 mg, HCT 12.5 mg or placebo. Patients were instructed not to take their trial 
medication on the clinic visit days, which were always in the morning at approximately 
the same time and within 23-26 h of the most recent study medication intake.  
 
Determination of UAE, renal function and blood pressure  
Patients were evaluated at baseline and after 6 weeks’ double-blind treatment. UAE was 
measured as the urinary albumin concentration in a morning urine sample (first 
micturition after getting out of bed) determined by a commercial immunoturbidimetry 
assay (BNII, Bade Behring Diagnostica), lower limit of quantification 2.2 mg/L and 
inter- and intra-assay coefficients of variation 4.4% and 4.3%, respectively. 
Microalbuminuria was defined as a UAE of 20-200 mg/L and macroalbuminuria as UAE 
> 200 mg/L (23). 
Urinary creatinine was determined in spot urine sample and serum creatinine was 
analysed. Estimated glomerular filtration rate (eGFR) was calculated from serum 
creatinine according to the Cockcroft formula (24).  
Seated trough blood pressure was measured three times at every clinic visit, with 
at least 2 min. between measurements, after the patient had been seated for 5 min. A 
manual cuff sphygmomanometer was used, with measurements to the nearest 2 mmHg. 
SBP was recorded as Korotkoff phase I and DBP as phase V. 
 
Statistics analysis 
For the pre-planned substudy, the analysis was performed on the per-protocol 
population, comprising all randomized patients in whom UAE was measured at baseline 
and after 6 weeks’ treatment and who met the substudy inclusion criteria. Based on our 
previous clinical experience, we assumed a 15% UAE reduction (log-transformed 
change 0.4 mg/L) to be clinically relevant. Based on data from the Prevention of Renal 
and Vascular Endstage Disease Intervention Trial (PREVEND IT) (25), the mean UAE 
is 31.3 mg/L (log 2.87) with a standard deviation (SD) of 85.5 (log 0.93) for patients 





Figure 1.  
Selection of patients for 
substudy analysis of effects 
of fixed doses of telmisartan 
20, 40 or 80 mg, 
hydrochlorothiazide (HCT) 
12.5 mg or placebo on 
urinary albumin excretion 
(UAE) from the 1039 
patients randomized to 
treatment in the ARAMIS 
study (22) 
 
change could be detected with 5% error probability and 80% power using a two-sided t-
test in a population of 81 patients per group. Baseline values are expressed as means and 
95% confidence intervals (CI), except for UAE which is expressed as median and 95% 
CI of the median range. Effects of treatment on UAE, expressed as percentage and 
absolute changes from baseline, and UAE-to-creatinine ratios were analysed by the non-
parametric Kruskal-Wallis test. In case of significance, pair-wise post-hoc comparisons 
between the separate groups were performed using the Mann-Wilcoxon-Whitney test. 
Blood pressure effects between the different treatment groups were analysed by a 
general linear model of covariance, adjusting for treatment and country effects with 
baseline as covariates.  
 
RESULTS 
Of the 1039 patients included in the ARAMIS study, spot morning urine samples were 
available both before and after the 6-week intervention and UAE was determined in 918 
patients (figure 1). There was a wide baseline distribution of UAE (> 2.2-901.6 mg/L, 
figure 2), with UAE detectable (i.e., above lower level of quantification of 2.2 mg/L) in 
614 patients (66.9%); these patients were included in the substudy analysis. 
Microalbuminuria (20-200 mg/L) was present in 70 (7.6%) patients and 
macroalbuminuria (> 200 mg/L) in 86 (9.4%). All treatment groups were comparable 
with regard to the number of patients with detectable UAE and baseline characteristics 
(table 1).  
 
Efficacy of different telmisartan doses 
After 6 weeks’ telmisartan treatment, the median (95% CI) reductions in UAE with 
telmisartan 20, 40 and 80 mg were 0.8 mg/L (0.5, 1.8), 1.2 mg/L (0.6, 2.1) and 0.3 mg/L  
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(n = 120) 
HCT 
12.mg 
(n = 140) 
All doses 
(n = 354) 
20 mg 
(n = 117) 
40 mg 
(n = 119) 
80 mg 
(n = 118) 
Male (%) 41.7 46.4 44.6 46.2 42.9 48.3 
Age (years) 64.0 (10.5) 63.6 (11.5) 62.6 (11.3) 62.7 (12.2) 62.2 (11.2) 62.8 (10.6) 
BMI (kg/m²) 27.3 (4.0) 27.5 (4.3) 28.0 (4.5) 28.0 (4.4) 27.8 (4.3) 28.1 (4.9) 
SBP (mmHg) 164.3 (7.8) 162.5 (8.3) 163.7 (8.0) 162.9 (7.9) 164.5 (8.2) 163.5 (8.0) 
DBP (mmHg) 83.3 (5.6) 83.5 (4.4) 83.4 (4.8) 83.7 (4.7) 83.5 (4.5) 83.1 (5.1) 
Pulse (bpm) 72.3 (9.8) 71.9 (9.5) 73.5 (10.0) 73.4 (9.5) 73.4 (10.0) 73.6 (10.4) 
eGFR (mL/min/1.73m2)a  95 (32) 102 (40) 106 (38) 103 (37) 105 (35) 109 (41) 












Type 2 diabetes (%) 7.5 10.7 11.3 11.1 12.6 10.2 
Microalbuminuria (%)c   10.0 9.3 12.7 14.5 8.4 15.3 
aCockcroft formula (24). bMedian (95% CI), cUAE 20-200 mg/L. BMI, body mass index. 
 
 
(0.0, 1.0), respectively. Mean (95% CI) reductions in seated trough SBP in the 20-, 40-
and 80-mg treatment groups were 15.1 mmHg (12.8, 17.4), 17.6 mmHg (15.3, 19.9) and 
16.9 mmHg (14.4, 19.5), respectively. Since no true dose–response was observed for 
either UAE or SBP, the values of the three telmisartan groups were combined (n = 354) 
for comparison with HCT and placebo.  
 
Efficacy of telmisartan compared with HCT and placebo on UAE 
The effects of the different treatments on absolute UAE values are shown in figure 3. 
Baseline UAE (median (95% CI)) in the total telmisartan group was 5.2 mg/L (4.2, 6.3). 
After treatment, median (95% CI) UAE was reduced significantly from baseline by 
14.1% (7.3, 21.8)  in  the telmisartan  group, where  as  non-significant  reductions  from 
baseline of 1.1% (-13.5, 16.0) and 2.7% (-0.9, 19.9) were observed in the HCT and 
placebo groups, respectively. The reduction in the telmisartan group differed 
significantly from that in the HCT group (p = 0.0165).  
Correcting for the urinary creatinine excretion revealed the same pattern: in the 
telmisartan group, UAE-to-creatinine ratio was significantly reduced by 12.7% (5.4, 
21.8). In the placebo groups, the median reduction was 8.0% (-7.9, 22.0) whereas there 
was a 1.8% (-25.3, 20.1) increase in the HCT group. Again, the difference between 





Distribution of baseline UAE in patients 
with spot urine evaluation (n = 918). 
Division of categories is made based on 
doubling of the successive intervals for 





In the telmisartan group, when the response was analysed based on baseline UAE (> 2.2-
20 mg/L (normoalbuminuria), > 20-200 mg/L (microalbuminuria) and > 200 mg/L 
(macroalbuminuria/overt proteinuria)), UAE reductions after 6 weeks’ telmisartan 




The effects of treatment on blood pressure (adjusted mean) are depicted in figure 4. 
Baseline (mean (95% CI)) SBP in the total telmisartan group was 163.7 mmHg (162.8, 
164.5); this was comparable to the SBP in the HCT and placebo groups of 162.5 mmHg 
(161.1, 163.9) and 164.3 (162.9, 165.8) mmHg, respectively. After 6 weeks, SBP was 
significantly reduced from baseline by 6.7% (5.4, 8.0) in the placebo group. Telmisartan 
treatment resulted in a larger reduction in SBP of 10.1% (11.0, 9.3). With HCT, a 9.1% 
(10.4, 7.7) reduction from baseline was detected. At baseline, the DBP in the total 
telmisartan group was 83.4 mmHg (95% CI 82.9, 83.9) and this was reduced by 2.7% 
(95% CI 2.0, 3.5) after 6 weeks’ treatment. In the placebo group, DBP did not change 
significantly from a baseline of 83.3 mmHg (82.2, 84.3), whereas a 2.0% (0.9, 3.1) 
reduction from a baseline value of 83.5 mmHg (82.8, 84.2) was detected in the HCT 
group. The differences in SBP and DBP reductions between HCT and telmisartan were 
not statistically significant. 
 
Safety 
Incidences of all-cause adverse events in the per-protocol population (n = 918) were 
17.6%,   14.0%   and   16.9%,   respectively,   for   telmisartan  20,  40  and  80  mg.  By  
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Adjusted mean (95% confidence 
intervals) urinary albumin excretion 
(ΔUAE) after 6 weeks’ treatment with 
placebo (n = 120), hydrochlorothiazide 
(HCT) 12.5 mg (n = 140); and telmisartan 






Figure 4.  
Adjusted mean (95% confidence 
intervals) changes in (a) systolic blood 
pressure (ΔSBP), (b) diastolic blood 
pressure (ΔDBP) and (c) urinary albumin 
excretion  (ΔUAE) after 6 weeks’ 
treatment with placebo (n = 120), 
hydrochlorothiazide (HCT) 12.5 mg (n = 
140) or telmisartan 20, 40 or 80 mg (n = 
354); * p < 0.0001; † p < 0.005;  











(n = 183) 
HCT 
 
12.5 mg  
 
(n = 185) 
20 mg  
 
(n = 180) 
40 mg 
 
(n = 187) 
80 mg 
  
(n = 183) 
Headache 4 (2.2%) 4 (2.1%) 3 (1.6%) 4 (2.2%) 4 (2.2%) 
Bronchitis 3 (1.6%) 2 (1.1%) 4 (2.2%) 3 (1.6%) 0 (0.0%) 
Upper respiratory tract infection 5 (2.7%) 1 (0.5%) 4 (2.2%) 0 (0.0%) 1 (0.5%) 
Back pain 1 (0.5%) 3 (1.6%) 3 (1.6%) 0 (0.0%) 1 (0.5%) 
Influenza-like symptoms 1 (0.5%) 2 (1.1%) 2 (1.1%) 1 (0.5%) 0 (0.0%) 
 
comparison, in the HCT and placebo groups, 19.8% and 18.7%, respectively, 
experienced an adverse event. The five most frequently reported events in any of the 
treatment groups are summarized in table 2. The total incidence of drug-related events 
was 3.0%, being comparable in the different treatment groups.  
No significant changes from baseline in clinical laboratory parameters were 
detected during the study. The mean (95% CI) calculated creatinine clearance decreased 
by 3.6 mL/min (1.3, 5.8) after 6 weeks’ treatment with telmisartan. A reduction of 2.1 
mL/min (-1.6, 5.7) was observed in the HCT group and an increase of 0.6 mL/min (-3.1, 
4.3) was detected in the placebo group.  
 
DISCUSSION 
This study demonstrates that, in patients with ISH and unselected for the degree of 
albuminuria at baseline, UAE was effectively reduced after telmisartan treatment, but 
not after treatment with HCT. This was despite similar reductions in SBP and DBP with 
the two treatments. Further analysis showed that this reduction in UAE was not only 
observed in patients with microalbuminuria or macroalbuminuria, but also in those with 
UAE within the range generally considered to be normal.  
Based on the outcomes of Antihypertensive and Lipid-Lowering Treatment to 
Prevent Heart Attack (ALLHAT) (26), Systolic Hypertension in the Elderly Program 
(SHEP) (27) and Systolic Hypertension in Europe trial (Syst-Eur) (28), The Seventh 
Report of the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure proposes the use of a diuretic as first-choice therapy 
for the treatment of ISH, with a long-acting calcium channel blocker as an alternative 
(29). However, it is noted that the choice of the initial agent is of less importance than 
the degree of blood pressure reduction achieved (29). The results of ARAMIS provide a 
different perspective, with telmisartan proving non-inferior to hydrochlorothiazide in the 
control of SBP (22). The results of our substudy show that telmisartan could have an 
additional benefit as it reduced UAE, whereas HCT did not. To our knowledge, there 
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have been no previous studies comparing the effect of an angiotensin II receptor blocker 
with that of HCT on UAE. However, there is evidence that targeting the RAAS using an 
angiotensin-converting enzyme inhibitor, as well as reducing blood pressure, decreased 
UAE in hypertensive diabetic patients, whereas HCT was ineffective despite comparable 
antihypertensive efficacy (30). Another study showed that, in normotensive diabetic 
patients, an angiotensin-converting enzyme inhibitor, but not HCT, reduced 
microalbuminuria (31).  
The reduction in UAE we observed in the short term among patients with varying 
degrees of albuminuria may confer clinically significant long-term cardiovascular 
benefit. Data from 40 000 individuals in PREVEND demonstrated that, after adjustment 
for other well-recognized risk factors, UAE is predictive of cardiovascular death in the 
general population (9). An individual with a UAE of 10-20 mg/L is reported to have 
28% higher risk of cardiovascular death than one with a UAE of 0-10 mg/L (9). 
Findings of the Heart Outcomes Prevention Evaluation (HOPE) study also demonstrated 
that any degree of albuminuria is a risk factor for cardiovascular events (19). A similar 
relationship exists between UAE and the development of renal damage, patients with 
high-normal UAE being at higher risk of developing microalbuminuria and 
macroalbuminuria (32).  
Whether or not a reduction in UAE, as a consequence of antihypertensive 
treatment—even when established within baseline ranges below the threshold for 
microalbuminuria—contributes to a risk reduction still needs to be established. 
Nevertheless, data from studies performed in both diabetic and non-diabetic 
microalbuminuric or macroalbuminuric patients show that a reduction in albuminuria 
using antihypertensive treatment favourably impacts on the incidence of end-organ 
damage (16-18,33). In particular, the beneficial effects of angiotensin-converting 
enzyme inhibitors and angiotensin II receptor blockers on cardiovascular and renal risk 
are predicted by their antiproteinuric activity (34). Currently, there are no data on 
changes in UAE from comparative studies conducted in patients with very low levels of 
UAE. Given that over 80% of the patients in our study had levels of UAE lower than the 
criteria for microalbuminuria, the significantly greater reduction in UAE with 
telmisartan compared with placebo is all the more striking. The effect on cardiovascular 
and renal risk reduction is uncertain at present, but deserves further examination. 
In the interpretation of our results, we acknowledge deficiencies. Firstly, 
although the reduction in UAE with telmisartan compared with placebo exceeded our 
prespecified limit for clinical significance, it did not reach statistical significance. 
Furthermore, SBP was also significantly reduced by placebo, although to a lesser extent 
than the two active treatments. It is, therefore, not feasible to distinguish between 
possible favourable effects of telmisartan or the more detrimental effect of HCT. 
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Secondly, our patient population displayed a marked variation in baseline UAE, ranging 
from < 2.2 mg/L to 901.6 mg/L. After treatment, the changes of UAE varied greatly in 
the three treatment groups. This wide distribution can be partly explained by the use of 
spot sampling, as opposed to 24-h collection of urine, and the collection of only one 
sample at baseline and one at the end of treatment. Nevertheless, correction of UAE for 
the creatinine excretion, which would allow for confounding factors, did not affect the 
overall pattern of our results. Thirdly, we did not observe a dose-response effect on 
UAE reduction with telmisartan. By contrast, in macroalbuminuric patients, uptitration 
of doses of RAAS-targeting agents may bring about additional UAE reduction (35). 
Since optimal blood pressure reduction is of great importance for optimizing outcome, it 
is interesting that no dose-response effect on SBP and DBP was detected with 
telmisartan. This suggests that telmisartan doses used in our study were at the plateau of 
the dose–response curve, both for the reduction of UAE and for blood pressure control. 
A previous study was unable to detect any significant linear trend in blood pressure 
reduction among telmisartan doses in the range 40-120 mg (36). 
In conclusion, treatment of ISH with the angiotensin II receptor antagonist 
telmisartan reduced UAE. In contrast, hydrochlorothiazide did not affect UAE, despite 
bringing about a similar reduction in blood pressure. With respect to optimal risk 
management, the telmisartan-induced reduction in UAE could be of additional benefit, 
although no cause-effect relationship has been demonstrated so far. Future studies 
should be directed at aggressive treatment of risk factors to establish the cardiovascular 
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